Gene Therapy for Blood Disorders Market Size, Share & Trends Analysis Report By Indication (Sickle Cell Anemia, ?-thalassemia, Hemophilia B, Hemophilia A), By Mechanism of Action (Gene Therapy, Gene Editing), By Region, And Segment Forecasts, 2025-2034
Global Gene Therapy for Blood Disorders Market Segmentation
Global Gene Therapy for Blood Disorders Market by Indication
- Sickle Cell Anemia
- β-thalassemia
- Hemophilia B
- Hemophilia A
Global Gene Therapy for Blood Disorders Market Based on Mechanism of Action
- Gene Therapy
- Gene Editing
Global Gene Therapy for Blood Disorders Market Based on Region
Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America
- U.S.
- Canada
Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy for Blood Disorders Market Snapshot
Chapter 4. Global Gene Therapy for Blood Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in Gene Therapy for Blood Disorders Market
4.10. Key Trends in the Market
Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis
5.1. Indication Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
5.2.1. Sickle Cell Anemia
5.2.2. β-thalassemia
5.2.3. Hemophilia B
5.2.4. Hemophilia A
Chapter 6. Market Segmentation 1: Mechanism of Action Estimates & Trend Analysis
6.1. Mechanism of Action Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Mechanism of Action:
6.2.1. Gene Therapy
6.2.2. Gene Editing
Chapter 7. Gene Therapy for Blood Disorders Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Indication, 2021-2034
7.1.2. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Mechanism of Action, 2021-2034
7.1.3. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.2.2. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.2.3. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.3.2. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.3.3. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.4.2. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.4.3. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.5.2. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.5.3. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Biomarin Therapeutics
8.2.2. Spark Therapeutics
8.2.3. Shire
8.2.4. bluebird bio, Inc.
8.2.5. CRISPR Therapeutics
8.2.6. Expression Therapeutics LLC
8.2.7. Medgenics
8.2.8. OrphageniX
8.2.9. Freeline Therapeutics
8.2.10. Errant Gene Therapeutics
8.2.11. Sangamo Therapeutics
8.2.12. Sigilon Therapeutics, Inc.
8.2.13. uniQure
8.2.14. Angiocrine Bioscience
8.2.15. Sanofi Genzyme
8.2.16. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Gene Therapy for Blood Disorders Market Size is estimated to grow at a 15.3% CAGR during the forecast period for 2025-2034.
Biomarin Therapeutics, Spark Therapeutics, Shire, bluebird bio, Inc., CRISPR Therapeutics, Medgenics, OrphageniX, Freeline Therapeutics, Errant Gene T
Gene Therapy for Blood Disorders market is segmented on the basis of indication, mechanism of action, and region.
North America region is leading the Gene Therapy for Blood Disorders Market.